GlassScriptPhysician profile
Stefanie D Eymar
NPI 1639579790
$35,693.00
in general payments reported to CMS, 2019-2025
70 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $988 · 2022: $711 · 2023: $8,848 · 2024: $13K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $30K · Travel and Lodging: $2,803 · Consulting Fee: $825 · Education: $83.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $30,282.39 |
| Travel and Lodging | $2,803.17 |
| Consulting Fee | $825.00 |
| Education | $83.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,369.46 | 2021-2025 | |
| Pfizer INC. | $2,366.07 | 2023-2025 | |
| Livanova USA, INC. | $2,074.32 | 2023-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Boston Scientific Corporation | $1,765.24 | 2024-2025 | Vercise |
| Tg Therapeutics, INC. | $1,455.36 | 2023-2025 | |
| Lilly USA, LLC | $1,420.43 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $1,324.98 | 2021-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $1,310.32 | 2023-2025 | Fintepla, Rystiggo, Briviact |
| Lundbeck LLC | $1,269.05 | 2023-2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $1,067.95 | 2023-2025 | Nuplazid, Daybue |
| Biogen, INC. | $1,051.41 | 2021-2025 | Tysabri, Vumerity, Tysabri |
| Emd Serono, INC. | $978.03 | 2023-2025 | Mavenclad, Mavenclad |
| Amgen INC. | $958.18 | 2021-2025 | Uplizna, Tezspire, Aimovig |
| Eisai INC. | $947.50 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $842.96 | 2023-2025 | Ultomiris, Soliris |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $820.79 | 2023-2025 | |
| Celgene Corporation | $661.25 | 2023-2025 | Zeposia |
| Sk Life Science, INC. | $566.10 | 2023-2025 | |
| Genentech USA, INC. | $550.70 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Argenx US, INC. | $531.35 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceuticals, INC. | $459.83 | 2021 | |
| Abbott Laboratories | $453.42 | 2023-2025 | Infinity, Eterna |
| Neurelis, INC. | $439.36 | 2023-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $414.34 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Axsome Therapeutics, INC. | $412.00 | 2025 | Symbravo |
| Otsuka America Pharmaceutical, INC. | $339.58 | 2023-2024 | Rexulti, Nuedexta |
| Genzyme Corporation | $298.98 | 2025 | |
| Mallinckrodt Hospital Products INC. | $294.74 | 2021-2025 | Acthar |
| Mdd US Operations, LLC | $273.19 | 2023-2025 | Gocovri, Gocovri |
| Avadel Cns Pharmaceuticals, LLC | $272.88 | 2024 | Lumryz |
| Merz Pharmaceuticals, LLC | $269.73 | 2023-2025 | Xeomin, Inbrija |
| E.R. Squibb & Sons, L.L.C. | $249.55 | 2023-2025 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $236.47 | 2023-2025 | Dysport |
| Vanda Pharmaceuticals INC. | $217.24 | 2024-2025 | Ponvory |
| Tanabe Pharma America, INC. | $202.76 | 2023-2025 | Radicava |
| Acorda Therapeutics, INC | $193.37 | 2023 | Inbrija |
| Jazz Pharmaceuticals INC. | $185.99 | 2023-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $149.74 | 2025 | Rexulti |
| Janssen Scientific Affairs, LLC | $141.78 | 2024 | |
| Idorsia Pharmaceuticals US INC | $131.21 | 2023-2024 | Quviviq |
| Microtransponder, INC. | $115.74 | 2025 | |
| Allergan, INC. | $111.52 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $106.46 | 2024-2025 | Purified Cortrophin Gel |
| Csl Behring | $102.21 | 2023-2025 | Hizentra |
| Sumitomo Pharma America, INC. | $98.17 | 2023 | Aptiom |
| Biohaven Pharmaceutical Holding Company LTD. | $94.73 | 2022 | |
| Impel Pharmaceuticals INC. | $88.86 | 2023 | Trudhesa |
| Scilex Pharmaceuticals INC. | $84.35 | 2024-2025 | |
| Harmony Biosciences LLC | $80.35 | 2024-2025 | |
| Banner Life Sciences, LLC | $80.34 | 2023-2024 | |
| Catalyst Pharmaceuticals, INC. | $77.09 | 2023-2025 | Fycompa |
| Octapharma USA, INC. | $70.81 | 2023 | Panzyga |
| C2n Diagnostics, LLC | $58.56 | 2025 | Precivityad2 |
| Ge Healthcare | $56.50 | 2024-2025 | |
| Tonix Medicines, INC. | $55.32 | 2024 | Zembrace Symtouch |
| Grifols USA, LLC | $53.76 | 2024-2025 | Gamunex-C |
| Alnylam Pharmaceuticals INC. | $51.28 | 2023 | Onpattro |
| Cycle Pharmaceuticals INC | $47.81 | 2025 | Tascenso Odt, Bafiertam |
| Amneal Pharmaceuticals LLC | $44.51 | 2025 | Crexont |
| Takeda Pharmaceuticals U.S.A., INC. | $37.12 | 2024 | Hyqvia |
| Sandoz INC. | $27.54 | 2025 | Tyruko |
| Horizon Therapeutics Plc | $25.42 | 2023 | Uplizna |
| Janssen Biotech, INC. | $24.86 | 2025 | |
| Upsher-Smith Laboratories LLC | $23.49 | 2023 | |
| Life Molecular Imaging LTD | $20.88 | 2025 | Neuraceq |
| Avion Pharmaceuticals | $20.84 | 2023 | Dhivy |
| Xeris Pharmaceuticals, INC. | $20.12 | 2023 | Keveyis |
| Averitas Pharma INC. | $19.52 | 2025 | Qutenza |
| Kyowa Kirin, INC. | $13.84 | 2023 | Nourianz |
| Sonex Health, INC. | $13.39 | 2025 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Eymar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.